189 related articles for article (PubMed ID: 22916799)
1. Cardiovascular effects of melatonin receptor agonists.
Paulis L; Simko F; Laudon M
Expert Opin Investig Drugs; 2012 Nov; 21(11):1661-78. PubMed ID: 22916799
[TBL] [Abstract][Full Text] [Related]
2. [Anti-hypertensive action of melatoninergic compounds].
Inoue Y
Nihon Rinsho; 2014 Aug; 72(8):1386-94. PubMed ID: 25167740
[TBL] [Abstract][Full Text] [Related]
3. Melatonin in cardiovascular disease.
Dominguez-Rodriguez A
Expert Opin Investig Drugs; 2012 Nov; 21(11):1593-6. PubMed ID: 22916801
[TBL] [Abstract][Full Text] [Related]
4. Melatonin receptors as therapeutic targets in the suprachiasmatic nucleus.
Pévet P
Expert Opin Ther Targets; 2016 Oct; 20(10):1209-18. PubMed ID: 27082492
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in melatonin receptor ligands.
Zlotos DP
Arch Pharm (Weinheim); 2005 Jun; 338(5-6):229-47. PubMed ID: 15952241
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the development of melatonin MT(1) and MT(2) receptor agonists.
Mor M; Rivara S; Pala D; Bedini A; Spadoni G; Tarzia G
Expert Opin Ther Pat; 2010 Aug; 20(8):1059-77. PubMed ID: 20533893
[TBL] [Abstract][Full Text] [Related]
7. Docking studies for melatonin receptors.
Alkozi HA; Sánchez Montero JM; Doadrio AL; Pintor J
Expert Opin Drug Discov; 2018 Mar; 13(3):241-248. PubMed ID: 29271261
[TBL] [Abstract][Full Text] [Related]
8. MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential.
Zlotos DP; Jockers R; Cecon E; Rivara S; Witt-Enderby PA
J Med Chem; 2014 Apr; 57(8):3161-85. PubMed ID: 24228714
[TBL] [Abstract][Full Text] [Related]
9. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.
Liu J; Clough SJ; Hutchinson AJ; Adamah-Biassi EB; Popovska-Gorevski M; Dubocovich ML
Annu Rev Pharmacol Toxicol; 2016; 56():361-83. PubMed ID: 26514204
[TBL] [Abstract][Full Text] [Related]
10. Circadian rhythms, melatonin and depression.
Quera Salva MA; Hartley S; Barbot F; Alvarez JC; Lofaso F; Guilleminault C
Curr Pharm Des; 2011; 17(15):1459-70. PubMed ID: 21476953
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of 1-(2-alkanamidoethyl)-6-methoxy-7-azaindole derivatives as potent melatonin agonists.
Jeanty M; Suzenet F; Delagrange P; Nosjean O; Boutin JA; Caignard DH; Guillaumet G
Bioorg Med Chem Lett; 2011 Apr; 21(8):2316-9. PubMed ID: 21420861
[TBL] [Abstract][Full Text] [Related]
12. Molecular cloning and pharmacological characterization of monkey MT1 and MT2 melatonin receptors showing high affinity for the agonist ramelteon.
Nishiyama K; Shintani Y; Hirai K; Yoshikubo S
J Pharmacol Exp Ther; 2009 Sep; 330(3):855-63. PubMed ID: 19556449
[TBL] [Abstract][Full Text] [Related]
13. The endogenous melatonin (MT) signal facilitates reentrainment of the circadian system to light-induced phase advances by acting upon MT2 receptors.
Pfeffer M; Rauch A; Korf HW; von Gall C
Chronobiol Int; 2012 May; 29(4):415-29. PubMed ID: 22489607
[TBL] [Abstract][Full Text] [Related]
14. Acute sleep-promoting action of the melatonin agonist, ramelteon, in the rat.
Fisher SP; Davidson K; Kulla A; Sugden D
J Pineal Res; 2008 Sep; 45(2):125-32. PubMed ID: 18298466
[TBL] [Abstract][Full Text] [Related]
15. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.
Kato K; Hirai K; Nishiyama K; Uchikawa O; Fukatsu K; Ohkawa S; Kawamata Y; Hinuma S; Miyamoto M
Neuropharmacology; 2005 Feb; 48(2):301-10. PubMed ID: 15695169
[TBL] [Abstract][Full Text] [Related]
16. Virtual discovery of melatonin receptor ligands to modulate circadian rhythms.
Stein RM; Kang HJ; McCorvy JD; Glatfelter GC; Jones AJ; Che T; Slocum S; Huang XP; Savych O; Moroz YS; Stauch B; Johansson LC; Cherezov V; Kenakin T; Irwin JJ; Shoichet BK; Roth BL; Dubocovich ML
Nature; 2020 Mar; 579(7800):609-614. PubMed ID: 32040955
[TBL] [Abstract][Full Text] [Related]
17. Autoimmune hepatitis in association with ramelteon.
Fourman LT; Robert Meyer B
J Clin Gastroenterol; 2013 Aug; 47(7):651-4. PubMed ID: 23632362
[TBL] [Abstract][Full Text] [Related]
18. Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies.
Leger D; Quera-Salva MA; Vecchierini MF; Ogrizek P; Perry CA; Dressman MA
Expert Opin Drug Saf; 2015; 14(11):1673-85. PubMed ID: 26393492
[TBL] [Abstract][Full Text] [Related]
19. 1,6-Dihydro-2H-indeno[5,4-b]furan derivatives: design, synthesis, and pharmacological characterization of a novel class of highly potent MT₂-selective agonists.
Koike T; Hoashi Y; Takai T; Nakayama M; Yukuhiro N; Ishikawa T; Hirai K; Uchikawa O
J Med Chem; 2011 May; 54(9):3436-44. PubMed ID: 21473625
[TBL] [Abstract][Full Text] [Related]
20. [A novel therapeutic drug: ramelteon].
Miyamoto M
Nihon Rinsho; 2009 Aug; 67(8):1595-600. PubMed ID: 19768947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
